REGULATORY

Gilead’s Bictegravir, BioCryst’s BCX7353 Get Orphan Status

January 7, 2019
The Ministry of Health, Labor and Welfare (MHLW) on December 27 granted orphan drug designation for Gilead Sciences’ HIV-1 infection treatment bictegravir and BioCryst Pharmaceuticals’ hereditary angioedema (HAE) drug BCX7353.BCX7353 was filed in Japan by Integrated Development Associates, which provides…

To read the full story

REGULATORY

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…